Will AbbVie's Neuroscience Franchise Aid Top-line Growth in Q1?

ABBV eyes a strong Q1 performance as neuroscience sales, led by Botox and Vraylar, are set to jump 22%, with newer drugs helping offset declines in legacy treat

Go to News Site